Sotera Health Co
$ 16.19
-1.22%
12 Jun - close price
- Market Cap 4,616,854,000 USD
- Current Price $ 16.19
- High / Low $ 16.59 / 16.08
- Stock P/E 39.49
- Book Value 2.18
- EPS 0.41
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.23 %
- 52 Week High 19.85
- 52 Week Low 10.79
About
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Analyst Target Price
$20.11
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-08 | 2025-05-01 | 2025-02-27 | 2024-11-05 | 2024-08-05 | 2024-05-02 | 2024-02-27 | 2023-11-01 | 2023-08-03 |
| Reported EPS | 0.18 | 0.26 | 0.26 | 0.2 | 0.14 | 0.21 | 0.17 | 0.19 | 0.13 | 0.26 | 0.21 | 0.08 |
| Estimated EPS | 0.17 | 0.2422 | 0.22 | 0.17 | 0.12 | 0.2019 | 0.18 | 0.16 | 0.12 | 0.26 | 0.2 | 0.09 |
| Surprise | 0.01 | 0.0178 | 0.04 | 0.03 | 0.02 | 0.0081 | -0.01 | 0.03 | 0.01 | 0 | 0.01 | -0.01 |
| Surprise Percentage | 5.8824% | 7.3493% | 18.1818% | 17.6471% | 16.6667% | 4.0119% | -5.5556% | 18.75% | 8.3333% | 0% | 5% | -11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.24 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SHC
2026-06-11 00:10:33
Certain stock options of Sotera Health Company (SHC) are under a 31-day lock-up agreement, preventing executive officers, directors, and selling stockholders from trading them. This lock-up period began on May 11, 2026, and concludes on June 11, 2026. The agreement is in place to stabilize the market after a recent offering.
2026-06-10 21:39:03
Sotera Health (SHC) is gaining momentum following Goldman Sachs' initiation of coverage, a strong Q1 2026 earnings beat, and clarity on Ethylene Oxide legal issues. The stock is currently trading at US$16.53, with analysts suggesting an intrinsic discount and upside to targets. While fair value estimates point to the stock being 18% undervalued with a target of US$20.13, its P/E ratio of 40x against a fair ratio of 26.5x suggests it might be expensive on that metric.
2026-06-10 14:09:39
Sotera Health (SHC) recently received coverage from Goldman Sachs, reported better-than-expected Q1 2026 earnings, and clarified legal exposures related to Ethylene Oxide. The company trades at an 18% undervaluation based on a fair value estimate of US$20.13, driven by strong cash generation and predictable revenue. However, its current P/E ratio of 40x appears expensive compared to a fair ratio of 26.5x and the industry average, suggesting less room for error.
2026-06-09 09:39:41
Geode Capital Management LLC has increased its stake in Sotera Health Company (NASDAQ:SHC) by 13.8%, purchasing an additional 476,365 shares. This acquisition brings their total holdings to 3.93 million shares valued at approximately $69.4 million. Sotera Health recently reported strong Q1 results, surpassing earnings and revenue expectations, and the stock maintains a "Moderate Buy" rating from analysts, despite a significant insider share sale by GTCR Investment XI LLC.
2026-06-08 14:10:12
Sotera Health Co faces investor scrutiny due to ongoing litigation risks alongside steady demand for its sterilization and lab testing services. The company is a key provider of sterilization for medical devices and pharmaceuticals, benefiting from regulatory requirements for product safety and contamination control. While essential to healthcare supply chains, its use of technologies like ethylene oxide subjects it to environmental scrutiny and potential legal challenges, which remain a significant factor in its valuation.
2026-06-07 15:40:26
Goldman Sachs recently initiated coverage on Sotera Health (SHC) with a "Buy" rating and a US$20.00 price target, highlighting the company's strong business model and progress in resolving personal injury lawsuits. This reassessment of legal risk by Goldman Sachs could significantly alter Sotera Health's investment narrative and risk-reward balance, despite ongoing concerns about unresolved ethylene oxide (EO) litigation in some states. The company's recent US$486 million equity offering also provides financial flexibility for emissions compliance and capacity investments, supporting its growth in sterilization volumes.
